Clouds Over CB Antagonists Cast Light On Rest Of Obesity Pipeline
Executive Summary
With big pharma's bet on cannabinoid-1 receptor antagonists for obesity shadowed by the safety concerns behind the withdrawal of Sanofi-Aventis' Zimulti (rimonabant) NDA, the weight of late-stage development could fall on centrally acting drugs that act on extensively-studied neurotransmitters, primarily serotonin, and peripherally acting agents that promise an improved side effect profile
You may also be interested in...
Merck Hopes To Make A Success Story of CETP Inhibitors And Obesity Drugs
Merck is hoping to find success where other firms have failed: its late stage pipeline includes two programs in drug classes where the lead candidates from other companies have not managed to gain approval
Merck Hopes To Make A Success Story of CETP Inhibitors And Obesity Drugs
Merck is hoping to find success where other firms have failed: its late stage pipeline includes two programs in drug classes where the lead candidates from other companies have not managed to gain approval
Novo Nordisk Sends Prandin To Sciele As It Prepares For Liraglutide
Sciele Pharma's deal with Novo Nordisk to market Prandin (repaglinide) doubles the firm's presence in the diabetes treatment market